{
    "nct_id": "NCT04178967",
    "official_title": "A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.",
    "inclusion_criteria": "* Male or female adults and adolescents (≥12 years and ≥40 kg)\n* Chronic atopic dermatitis (according to American Academy of Dermatology Consensus Criteria) that has been present for ≥1 year before the screening visit\n* Eczema Area and Severity Index (EASI) score ≥16 at the baseline visit\n* Investigator Global Assessment (IGA) score ≥3 (scale of 0 to 4) at the baseline visit\n* ≥10% body surface area (BSA) of atopic dermatitis involvement at the baseline visit\n* History of inadequate response to treatment with topical medications; or determination that topical treatments are otherwise medically inadvisable\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "* Prior treatment with dupilumab or tralokinumab\n* Treatment with topical corticosteroids, calcineurin inhibitors or phosphodiesterase-4 inhibitors such as crisaborole within 1 week prior to the baseline visit\n* Treatment with any of the following agents within 4 weeks prior to the baseline visit:\n\n  * Immunosuppressive/immunomodulating drugs (e.g., systemic corticosteroids, cyclosporine, mycophenolate-mofetil, IFN-γ, Janus kinase inhibitors, azathioprine, methotrexate, etc.)\n  * Phototherapy and photochemotherapy (PUVA) for AD\n* Treatment with the following prior to the baseline visit:\n\n  * An investigational drug within 8 weeks or within 5 half-lives (if known) of baseline, whichever is longer\n  * Cell-depleting biologics, including to rituximab, within 6 months of baseline\n  * Other biologics within 5 half-lives (if known) or 16 weeks of baseline, whichever is longer\n* Treatment with a live (attenuated) vaccine within 12 weeks of the baseline visit or planned during the study\n* Uncontrolled chronic disease that might require bursts of oral corticosteroids, e.g., co-morbid severe uncontrolled asthma\n* Evidence of active acute or chronic hepatitis\n* History of human immunodeficiency virus (HIV) infection or positive HIV serology\n* History of malignancy, including mycosis fungoides, within 5 years before the screening visit, except completely treated in situ carcinoma of the cervix, completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin\n* Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study",
    "miscellaneous_criteria": ""
}